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Breast cancer is the most frequently diagnosed cancer among women and a leading cause of cancer-related death. 
Despite many available diagnostic tools and techniques, tumor heterogeneity and molecular diversity of breast 
cancer tumors require new biomarkers in clinical practice. A potential diagnostic test can be built based on few 
biomarkers. Those biomarkers may not be specific and sensitive enough to be a single diagnostic tool, but might 
be useful as a set of biomarkers e.g. CEA, CA15-3, MammaPrint®, HER2 and BRCA1, 2. The second group of potential 
biomarkers are microRNAs. Changes in miRNA and altered genes expression may contribute to the development of 
breast cancer and metastases. Integration of proteomics, genomics, and metabolomics data is necessary to discover 
a new panel of biomarkers. 
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Breast cancer — introduction
Breast cancer is the first malignant neoplasm in terms of 
incidence in women in Poland and worldwide (more than 
1/5 of all cases) and the most frequent cause of death due 
to malignant neoplasms in women [1]. The incidence of this 
type of cancer increased more than twice in the last three 
decades — with about 16 000 new cases reported in 2010 
[2]. Breast cancer is a heterogeneous cancer associated with 
many etiological factors [3]. Among the factors predisposing 
to the development of this type of cancer are: being female, 
age over 50 years, early menstruation and late menopause, 
as well as a number of environmental and genetic factors [4].
Breast cancers are divided into two main histological 
types: pre-invasive in situ cancer and invasive cancers. Pre-
-invasive cancers account for about 15% to 30% of all cases 
and are divided into: lobular carcinoma in situ (LCIS), charac-
terized by the growth of the mammary glands, and ductal 
carcinoma in situ (DCIS), where cancer cell growth affects 
the epithelium of the mammary gland, without signs of 
stroma infiltration. Ductal carcinoma in situ, a precursor of 
invasive cancer, is heterogeneous in terms of biology and 
morphology. In 80% of cases these cancers are detected 
during mammography (in the form of calcifications), the 
remaining 20% are detected in the form of cystic tumors, 
Paget’s disease, star-shaped lesions or nipple discharge. 
Lobular carcinomas in situ are characterized by the growth 
of lobular epithelium cells, which completely fills at least 
50% of the follicles, these cancers do not form tumors and 
calcifications, and therefore they are not detected during 
mammography.
The most common invasive cancer is ductal cancer, 
which occurs in about 70–85% cases. Lobular carcinoma in 
the mammary glands accounts for about 15% of the cases. 
Both types of cancer are characterized by an increased risk of 
distant metastases. Rare types of invasive breast cancer are: 
tubular/cribriform (6%), mucous (2%), medullary (2%), papil-
lary (1%) and metaplastic (< 1%) cancers. Due to significant 
differences in the biology of invasive cancers, a 3-stage histo-
logical malignancy evaluation was additionally introduced. 
Common features of infiltrating cancers are: infiltration in 
all directions, “orange peel”, nipple pulling, metastases into 
lungs, bones, liver, adrenal glands and brain. Metastases to 
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lymph nodes are the most important prognostic factor. In 
the absence of distant metastases, it is estimated that the 
10 years overall survival reaches 80%, while the involvement 
of one to three lymph nodes reduces the 10 years overall 
survival to 35–40%.
Molecular markers currently used to diagnose 
breast cancer
A molecular marker may be a gene, transcript or protein 
(or sets of such molecules) whose condition and quantity 
is related to the risk, occurrence or advancement of the 
disease. Cancer markers by origin can be divided into two 
types. The first are markers produced by cancer cells and 
these are specific antigens of tumors, i.e. TSA (tumor specific 
antigens). The second type of cancer markers are antigens 
accompanying cancer produced by normal cells as a result of 
their response to pathological changes in the environment, 
also referred to as TAA (tumor associated antigens) [5]. The 
markers can be nucleic acids, proteins, lipids and other me-
tabolites, but also whole tumor cells, which can be found in 
blood (CTC — circulating tumor cells) [6]. Molecular markers, 
including cancer markers, can be detected in the patient’s 
blood, urine or tissue. Depending on the method of material 
collecting, markers can be divided into invasive and non-
-invasive [7]. Invasive markers are characterized by the need 
for surgical intervention in order to collect the material for 
testing. This group includes immunohistochemical markers 
such as ER, PR, HER2, Ki-67, p53, whose analysis requires 
biopsy or tissue removal during surgery. The advantage of 
this type of markers is their high specificity, which makes 
them commonly used for accurate diagnosis and prognosis 
of the disease. Non-invasive markers are proteins, enzymes, 
hormones or circulating tumor cells present in body fluids, 
such as serum, plasma, nipple secretion, tears, urine and 
saliva [8]. Collection of material for testing is not problema-
tic and burdensome for the patient, although markers are 
evaluated in non-cancer material, which means that para-
meters such as sensitivity and specificity are debatable. Im-
munological methods, mass spectrometry, flow cytometry 
[9] and qRT-PCR [10] are used to determine these markers. 
In the analysis of molecular markers, the most important 
parameters are sensitivity and specificity as well as their 
predictive value. The sensitivity of the marker reflects the 
number of correctly identified samples from ill patients and 
it is calculated as the ratio of true positive results to the sum 
of true positive and false negative results (value expressed 
as a percentage). The specificity of the marker reflects the 
number of healthy people misclassified as a group of sick 
persons and it is calculated as the ratio of true negative 
results and the sum of false positive and false negative 
results. An ideal marker should have 100% sensitivity and 
specificity. A positive predictive value (PPV) indicates a high 
probability of disease occurrence when a marker is detected 
and it is calculated as the ratio of the number of true positive 
results to the sum of true and false positive results. Similarly, 
a negative predictive value (NPV) indicates a low probability 
of disease presence in the absence of a detected marker. The 
following are the markers currently used in clinical practice 
to diagnose breast cancer.
Status of hormonal receptors
The hormonal status of patients is important both in the 
etiology of the disease and in response to treatment, so the 
choice of treatment depends on the expression of individual 
receptors. Estrogen receptor (ER) expression is found in 70% 
of breast cancers. It has two isoforms: α and β, in clinical 
practice ERα expression is mainly determined. The presence 
of β form in the tumor is associated with better prognosis and 
a longer disease free survival [11]. Patients with ER+ status 
have significantly better response to anti-estrogenic treat-
ment (e.g. tamoxifen) than patients with ER- [12]. Moreover, 
in the work of Guo et al. it has been shown that high ERβ 
concentration in patients impair the efficiency of endocrine 
therapy, while low ERβ concentrations in patients treated 
with hormones were correlated with prolonged disease free 
survival in relation to the group without hormonal treatment 
[13]. Estrogens, by binding to their receptors, induce the 
synthesis of the progesterone receptor [14]. Clinical trials 
have shown that patients classified as ER-/PR- have a higher 
mortality rate than ER-/PR+ patients, which was associated 
with a better response to hormone therapy in the latter group 
[15]. The expression of ER and PR receptors is not constant and 
changes with the progression of the disease [16].
HER2 receptor status
Important prognostic factors in breast cancer inclu-
de HER2 receptor status (human epidermal growth factor 
receptor 2). HER2 is a glycoprotein acting as a membrane 
receptor, belonging to the family of receptors for epidermal 
growth factors. Protooncogen HER2/neu/eRBb-2 is detec-
ted in multiplied form in 10–35% of breast cancer patients, 
which is an important adverse prognostic factor in both ear-
ly and advanced breast cancer [17]. The first overexpression 
of this receptor was confirmed in breast cancer patients by 
the Van de Vijver group in 1988. In the same year the Berger 
group showed a correlation between HER2 receptor ove-
rexpression and lymph node status (N) and tumor size [18, 
19]. In the following years, overexpression of this receptor 
was associated with a more aggressive cancer phenotype 
and worse prognoses [20]. The basic test for assessing the 
HER2 receptor status is an immunohistochemical procedure 
supplemented by FISH gene amplification test (fluorescent 
hybridization in situ), recommended each time when the 
result of protein expression determination is ambiguous. 
The antibody directed against the extracellular domain of 
HER2 receptor is trastuzumab. This antibody is used in the 
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adjuvant treatment of HER2 patients, reducing the risk of 
relapse as well as mortality in early stage cancer patients 
[21]. HER2 overexpression has been shown to be associated 
with an increased risk of cerebral metastases in patients with 
advanced cancer [21, 22]. Moreover, quantitative measure-
ments of HER2, HER3 and p95HER2 protein levels allow for 
detailed analysis of their potential prognostic value. This 
assessment showed that the relationship between HER2 
expression and overall survival of patients receiving lapa-
tinib after trastuzumab progression is U-shaped with the 
best response among patients with moderate HER2 ove-
rexpression and high p95HER2 expression [23]. Moreover, 
quantitative assessment of p95HER2 and HER2 expression 
may be useful in assessing the risk of cerebral metastases, 
which requires further research [24].
Molecular subtypes evaluated on the basis of gene 
expressions
Based on the characteristics of gene expression profile in 
tumour tissue, four breast cancer subtypes can be distingu-
ished as luminal type A, luminal type B, basal cell type and 
HER2-positive, also called non-luminal [25, 26]. Luminal type 
A is characterized by high expression of genes associated 
with estrogen receptor activity and low expression of genes 
associated with proliferation and genes associated with 
HER2 receptor expression. Luminal type B is characterized 
by positive ER status combined with low expression of genes 
associated with this receptor and higher expression of pro-
liferation-related genes than in type A assessed by the Ki-67 
designation. A team of panellists from St. Gallen considered 
the degree of malignancy and Ki-67 expression to be factors 
that can be used to distinguish between luminal type A and 
subtype B-like tumours. This is important in the prognostic 
assessment, which is better in type A [27]. The third type is 
basal-like breast carcinoma, also called triple negative due 
to the absence of estrogen and progesterone receptors and 
the lack of expression of the HER2 receptor — as a conse-
quence, there is no expression of genes associated with 
these receptors. A group of patients with this type of cancer 
with cerebral metastases is particularly interesting; in their 
case the use of biological markers (CK 5/6, HER1, c-KIT) may 
help to differentiate the basal subtype of a like and no-like 
one, but their clinical usefulness is ambiguous [28]. The last 
molecular subtype of breast cancer is characterized by HER2 
overexpression combined with absence of ER and PR [22].
Molecular breast cancer subtype can be assessed by 
performing one of several available genomic tests. The 
Oncotype DX® test allows for analysing the expression of a 
panel of 21 genes to estimate the individual risk of relapse 
in patients diagnosed with early stage breast cancer. This 
test also allows for individualizing the therapy because of 
the information about the chemotherapy benefits. A risk as-
sessment of relapses based on a 21-gen test result for breast 
cancer predicts the benefits of chemotherapy if it is high, 
while a low risk of relapses in the absence of chemotherapy 
if it is low. In addition, complementary hormone therapy and 
chemotherapy combined with hormone therapy showed 
similar efficacy in women with hormone positive, HER2-ne-
gative, N0 breast cancer, who obtained an indirect test result, 
although the benefits of chemotherapy were reported in 
some women aged 50 years and younger [29, 30].
Another multi-gene diagnostic assay is MammaPrint®. 
This test is based on an analysis of 70 gene signatures. It is 
used by clinicians to choose a therapy that minimizes the 
risk of relapse. The Breast Cancer Index test analyses the 
expression of genes associated with two types of signal pa-
thways — estrogen-related and cell proliferation, with its use 
it is possible to estimate the benefits of endocrine therapy 
as well as the risk of relapse [31]. In addition, recent results 
of a randomized EORTC 10041/BIG 3-04 MINDACT study 
showed the usefulness of molecular evaluation (BluePrint 
and MammaPrint) of breast cancer subtype compared to 
immunohistochemical evaluation. On the basis of molecular 
evaluation 54% of patients with luminal B subtype could be 
qualified to luminal A subtype with similar treatment results. 
Therefore, molecular classification may help to identify a lar-
ger group of patients with a low risk of relapse compared 
to the more modern classification methodology, including 
the high quality assessment of the Ki-67 [32].
Multi-gene panels are better than traditional predictive 
factors in predicting clinical response and identifying women 
who can safely skip chemotherapy. The available evidence 
confirms the clinical validation of multi-gene panels, of which 
Oncotype DX® and MammaPrint® have the strongest eviden-
ce to support their clinical usefulness and decision making 
effectiveness in luminal breast cancer [33, 34].
PAM-50 is a qPCR-based assay. It enables the analysis 
of the expression of 50 genes based on biopsy material 
allowing to classify cancers into subtypes and predicts the 
risk of relapse (ROR) after 10 years. The additional inclusion 
of known clinical and pathological factors significantly in-
creases its predictive value [25, 35, 36]. The PAM-50 test 
result may help to identify a group of patients who may 
benefit from the additional use of taxans in complementary 
treatment [37]. Further clinical studies should assess the 
ability of the PAM-50 test and other gene analysis to divide 
patients and provide individual treatment depending upon 
the predicted risk of relapse and metastases. Especially, 
many problems remain to be solved before multi-gene 
panels have a greater impact on breast cancer treatment, 
such as accurate prediction of late relapse in ER-positive 
breast cancer or greater access to multi-gene panels [34].
Patient’s genetic profile
The most important genetic factors that determine 
predisposition to breast cancer are the BRCA1 and BRCA2 
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genes. These genes are classified as so-called suppressor 
genes, and their protein products are involved in the re-
gulation of transcription, repair of damaged DNA and in 
the differentiation process. Germinal mutations within the 
BRCA genes are associated with an increased risk of disease 
(up to 70% for people without mutations). The frequency 
of different types of mutations within these genes depends 
on the ethnic group and geographical region [38, 39]. The 
assessment of the occurrence of mutations in BRCA genes is 
important not only as a risk factor for cancer, but also plays 
an important role in the choice of systemic treatment. It 
has been shown that in advanced breast cancer patients 
carrying mutations benefit more from the use of carboplatin 
compared to docetaxel [40]. In addition to mutations in the 
BRCA genes, other genetic changes are associated with an 
increased risk of breast cancer. These genes include: TP53 
(in patients with Li-Fraumeni syndrome), STK11 (in patients 
with Peutz-Jeghers syndrome) and PTEN. In addition, mu-
tations in genes such as CHEK2, ATM, PALB2 and BRIP1 were 
also found in the studied families with breast cancer [41].
Proliferation potential
Ki-67 protein is the protein that enables the assessment 
of the proliferation rate in the malignant tissue. Patients with 
more than half of the tumour cells showing expression of 
this factor are at higher risk of recurrence. Furthermore, high 
expression of this factor is associated with worse prognosis, 
but with a better response to chemotherapy [42, 43]. The Ki-67 
protein expression may be an independent prognostic factor 
determining the disease free survival, however, it requires stan-
dardization of parameter evaluation [44]. A significant factor 
in the assessment of Ki-67 expression is a properly performed 
analysis by qualified professionals. Although the data concer-
ning the standardization of scores are encouraging, there are 
still discrepancies between departments of pathomorphology. 
Moreover, the information on Ki-67 expressions has a signifi-
cant influence on the decision making process regarding the 
use of systemic treatment. In the case of high expression of Ki-
67, chemotherapy may be considered even for the early stage 
breast cancer patients and ER positive tumours [27].
Cancer markers are also detected in serum or plasma. The 
most commonly used cancer markers are glycoproteins pre-
sent in the membrane of cancer cells. These include mucins 
such as CA15-3 (cancer antigen 15-3), which is a product of the 
MUC1 gene. Other members of this marker group are: PEM, 
MCA, MSA and CA125 (cancer antigen 125). Their level may be 
elevated in the course of several types of cancer (apart from 
breast cancer these are ovarian cancer, endometrial cancer, 
fallopian tube cancer or lung cancer). Another cancer marker 
used in diagnostics of many types of cancers, including breast 
cancer (especially in ductal cancers), is CEA (carcinoembryonic 
antigen), which is a glycoprotein of blood serum [45]. CEA 
together with CA15-3 are considered to be a markers for re-
lapse. CA15-3 is overexpressed in 90% of breast cancer cases, 
but it is not (similarly as CEA) a marker specific for this type of 
cancer. The concentration of these markers increases with the 
size of the tumour, and an increase in their concentration was 
also observed in hepatitis, benign breast and ovarian lesions, 
cancer of the uterus, ovary or lung. CA15-3 is characterized 
by low diagnostic sensitivity at the early stages of the disease 
(I, II), because it varies between 20% and 30%, therefore it is 
not suitable for screening, but this marker is used in the dia-
gnosis of metastases [46]. In advanced stages of the disease 
(stage III and IV) the sensitivity of CA15-3 increases to 70%. 
CEA synthesis is intensified in breast cancer cells as well as in 
cells derived from colorectal, pancreas and stomach cancer. 
For this reason, CEA is characterized by limited sensitivity 
and diagnostic specificity. Like CA15-3, this marker is not 
suitable for screening, but it is used for the detection of re-
lapses and distant metastases. The positive predictive value 
of CEA concentration increase for progression confirmation 
is over 90%, so it is considered a universal marker of cancer 
metastases [47].
Another group of markers used in the diagnosis of bre-
ast cancer are cytokeratins, which are insoluble structural 
proteins of epithelial cells, the presence of which in the 
blood indicates progressive cell death processes in tissues. 
Cytokeratin 8, 18 and 19 fragments present in serum are 
potential markers for the diagnosis of early stages of breast 
cancer [48, 49]. TPA (tissue polypeptide-specific antigen) 
is a peptide complex associated with cytokeratin 18. This 
marker is related to the proliferative abilities of tumour cells, 
the presence of this complex in blood is an unfavourable 
factor, as it indicates a rapid relapse of the disease [50, 51].
New molecular factors with potential use in 
breast cancer diagnostics
The “classic” breast cancer biomarkers applied so far 
are not used in screening. The main reasons are their low 
concentration in non-advanced cancers (in situ) and low 
sensitivity and specificity at the early stages of the disease 
[52]. These markers are usually used to monitor a possible 
relapse during the treatment, as well as after the treatment 
[53]. Moreover, there are no data on the possibility of using 
these markers in the risk assessment of metastases in pa-
tients with non-advanced breast cancer, which are the main 
cause of treatment failure in this group of patients. For this 
reason, an intensive research is underway to identify markers 
with potential use in early diagnosis and risk assessment 
of metastases, especially in patients with early detection 
of cancer. Several groups of potential biomarkers tested in 
this context are presented below.
Metalloproteinases
Among the new cancer markers, also tested for the-
ir usefulness in the diagnosis of breast cancer, there are 
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metalloproteinases, which as proteolytic enzymes enable 
digestion of extracellular matrix components and numerous 
molecules on the cell surface, and thus participate in the 
formation of metastases and angiogenesis. Metalloprote-
inases of potential diagnostic significance include MMP-9. 
It is believed that the concentration ratio of MMP-9/TIMP-1 
(a specific MMP-9 inhibitor) may be prognostic in breast 
cancer [54].
Nuclear proteins related to proliferation activities
PCNA (proliferating cell nuclear antigen) is a non-histo-
ne nuclear protein that participates in both DNA synthesis 
and in the response to genetic material damage. In clinical 
practice it is considered as a marker of mitotic activity, just 
like Ki-67 in breast cancer patients. Phosphorylation of this 
protein in tyrosine at position 211 is positively correlated 
with the increase in proliferation of cancer cells, and thus it 
is a prognostic disadvantage [55, 56].
Chemokines and their membrane receptors
The CCR2 chemokine receptor is a membrane protein, 
specifically binding with CCL2 chemokines. These chemo-
kines are secreted by monocytes and macrophages. The 
overexpression of this chemokine and its receptor in breast 
cancers metastases to the lungs and bones was demonstra-
ted [57, 58]. Moreover, CCL2 correlates with the advance-
ment of the breast cancer and is a prognostic factor for the 
estimation of metastases free survival/relapse free survival 
[58]. Under normal conditions CCL2 together with CCL5 che-
mokine stimulate the migration of monocytes and T cells to 
damaged or infected sites. These chemokines show higher 
expression in tumor tissues than in normal tissues, and CCL5 
is a characteristic chemokine for patients with triple negative 
molecular subtype [58–60]. CXCR4 (C-X-C chemokine recep-
tor type 4) is a transmembrane protein receptor responsible 
for the migration of cells from the primary tumor to the 
lungs, bones and lymph nodes. Its mechanism of action 
is based on chemotaxis, as these organs release CXCL12 
chemokine, which is a ligand of this receptor. In patients 
with triple negative breast cancer, high expression of this 
receptor may indicate a more aggressive tumor phenotype 
than in patients with low CXCR4 levels [61].
Membrane proteins
Integral cell membrane proteins that form membrane 
invaginations (so-called caveoles) are caveolins, which take 
part in the transmission of cellular signals and in alveolar 
transport. The expression of CAV1 and CAV2 caveolins is 
often associated with triple negative cancers and a high 
histological advancement of the disease [62]. Caveolin 1 
(CAV1) can be a marker of oxidative stress, and its level 
seems to be related with response to chemo- and radio-
therapy [63].
Microtubule-associated proteins
One of the methods of breast cancer treatment is the 
administration of drugs which affect the structure of mi-
crotubules. Decomposition or stabilization of these cellular 
structures reduces cell proliferation. One of the proteins 
associated with microtubules is the ATIP3 protein, which 
prolongs the time of cell division, thus reducing the number 
of dividing cells. Patients with invasive breast cancer and 
metastases showed significantly decreased levels of ATIP3 
protein and its encoding gene (MTUS1) by 74.7% and 62.4% 
respectively in the group with metastases. These data indi-
cate ATIP3 protein as a therapeutic target and as a potential 
biomarker for development of metastases [64, 65].
Transcription factors
GATA4 is a transcription factor, which plays an important 
role in cancer progression (expression of genes regulated by 
this factor is correlated with metastases and HER2 status). 
This marker is particularly useful for patients with invasive 
ductal carcinoma and may be a prognostic factor for this 
group of patients [66]. Transcription factor HIF2α activates, 
among other things, the expression of gene encoding MMP-
9 metalloproteinase. In immunohistochemical studies based 
on material from breast cancer patients, the expression of 
these proteins was found in 60% and 66% respectively. Both 
HIF2α and MMP expression correlate with stage of the breast 
cancer, while high HIF2α protein expression correlates with 
short overall survival [67].
Growth factors
Growth factors such as EGF, HGF, IGF, VEGF and TGF-β 
are examined both for cancer risk and tumor progression. 
TGF-β as a biomarker is useful as a prognostic information 
for breast cancer patients in stages I to III. It is believed that 
elevated TGF-β levels may characterize patients at risk of 
relapse [68].
Protein panels detected by proteomics methods
Proteomics studies allow us to get to know the full set 
of proteins present in a given tissue, their structure, mo-
dification and mutual relations. Information on the quali-
tative and quantitative composition of cellular proteins 
can be generated using a number of techniques (mainly 
mass spectrometry), and for the final result of such studies, 
correct bioinformatic data processing and their integration 
from various fields is crucial. Clinical proteomics makes it 
possible to learn about changes in body tissues and fluids 
during the development of the disease and during therapy 
[69, 70]. Proteomics methods are also used for the “unsupe-
rvised” search for proteins of potential importance for the 
diagnosis of breast cancer. Table I summarizes a series of 
studies aimed at detecting potential biomarkers of breast 
cancer in both tumor tissue and body fluids. It should be 
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noted that potential breast cancer markers detected with 
proteomics methods in serum and plasma are dominated 
by inflammatory proteins. It is estimated that the higher 
level of amyloid (SAA) and S100A4 protein increases the risk 
of metastases [71–73]. Moreover, the risk of breast cancer 
seems to be correlated with the level and modification of 
apolipoproteins [74, 75].
Circulating tumor cells
The presence of circulating tumor cells (CTC) in the 
blood is an important diagnostic and prognostic factor in 
many types of cancer [84]. It is believed that the CTC level 
may be a useful prognostic marker at early stages of breast 
cancer and may correlate with the level of invasiveness and 
aggressiveness of the tumor [85]. CTC can also be used as 
research material for other biomarkers. It was found that 
TFF1 protein present in CTC in breast cancer patients corre-
lates strongly with bone metastases [86]. Moreover, patients 
with high ERβ expression in circulating tumor cells showed 
good response to hormonal treatment [87].
MicroRNA
In the last decade, intensive research on microRNA has 
been carried out in terms of its diagnostic and prognostic 
usefulness. MicroRNA are short (21–24 nucleotides), non-co-
ding RNA molecules that typically bind to the 3’UTR regions 
present in mRNA transcripts and regulate the expression 
level of many genes. Molecules of miRNA can be detected 
in both tissues and body fluids. Probably cancer-related 
miRNA molecules enter the bloodstream when tumor cells 
die. Another possibility is the active secretion of miRNA mo-
lecules through exosomes [88]. In the work of Wu et al. [89] 
more than 800 different miRNA molecules were detected in 
breast cancer patients. Two of them, mi-R357 and mir-122, 
showed a strong correlation with the outcome of treatment 
and thus with the choice of treatment. Their analysis sho-
wed that myrrh-497 expression correlates negatively with 
the advancement of the disease, lymph node metastases 
and tumor size. However, there was no correlation with 
classical markers such as ER, PR or p53 status. In turn, the 
Huang group showed, both in vitro and in vivo, that mir-373 
and mir-520c molecules stimulate the migration of cancer 
cells and their invasiveness [90–92]. The loss of suppressor 
miRNA molecules such as: miR-206, miR-17-5p, miR-205, 
miR-125b, miR-200, miR-34a, miR-27b, miR-126, miR-101, 
miR-145, miR-205 and miR-31 and/or oncogen overexpres-
sion of miRNA molecules (miR-21, miR-155, miR-10b, miR-
373, miR-520c, miR-27a, miR-221/222) were observed in 
breast cancer patients [93]. In 2012, the Schrauder group 
carried out micromatrix analyses of miRNA molecules in 
peripheral blood of 48 patients at early stages of the disease 
and 57 healthy people. There were 59 miRNA molecules 
differentiating these two groups of women, 13 of which 
were characterized by overexpression and 46 by decrease in 
Table I . Potential biomarkers for breast cancer identified by different methods of proteomics
Potential biomarker Method used Material used for testing Bibliography
CBP1, PDZ, LIM, 
PDLIM2, RNF25
iTRAQ-2D LC MS/MS
immunohistochemistry
24 samples from metastatic lymph nodes, 24 
samples from non-metastatic lymph nodes, 
48 samples taken from patient tumors
Bouchal et al. [76]
TCEAL4, AZGP1, S100A10, CAPS ALDH6A1, 
AHNAK, FBP1, S100A4, MX1, HSP90AB1, 
PDXK, GFPT1, RAB21, 
iTRAQ 12 samples taken from tumors from patients with 
recurrence
12 samples taken from tumors from patients 
without symptoms of the disease
> 7 years
Johansson et al. [77]
ECM1, MAST4, 
Filaggrins
Label-Free LCMS/
MS
20 urine samples taken from breast cancer 
patients
20 urine samples taken from healthy women
Beretov et al. [78]
15SFAA UPLC–MS 27 saliva samples from breast cancer patients
28 saliva samples from healthy women
Cheng et al. [79]
Apolipoprotein C1, carbonic anhydrase 1, 
L1CAM
MRM- MS 80 plasma samples from breast cancer patients
80 plasma samples from healthy women
Lee et al. [80]
Apolipoprotein AI, POTEE, HPX Filaggrins
MS
20 tissue samples taken from breast cancer 
patients
 Cine et al. [81]
Apolipoprotein H, ApoCL, apolipoprotein 
AI, C3a, TTR
SELDI-TOF MS
Western blott
MALDI-TOF/TOF
MS
99 blood samples from breast cancer patients
51 blood samples from healthy women
Chung et al. [70]
Parathyroid hormone-related protein SELDI-TOF MS 111 plasma samples from breast cancer patients Washam et al. [82]
Serum amyloid
Haptoglobin
ELISA 118 blood samples from breast cancer patients
51 blood samples from
healthy women
Zhang et al. [83]
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relation to the control group [94]. These reports indicate the 
enormous information potential of miRNA research, both 
as factors regulating many processes in the cell, as well as 
their diagnostic and prognostic potential.
Summary
The results of advanced breast cancer treatment are still 
unsatisfactory, therefore, it is necessary to develop new dia-
gnostic tests for the early detection of the disease. Moreover, 
a panel of prognostic and predictive biomarkers is awaited, 
which would allow for individualization of patients treat-
ment. Personalized medicine assumes a systemic approach 
to the disease. The key to success may be the integration of 
molecular data: genomic, proteomics and metabolic toge-
ther with clinical parameters.
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